Licensed Ebola vaccine sparks immune cells that recognize a second deadly ebolavirus

The ongoing outbreak of Bundibugyo ebolavirus (BDBV) in the Democratic Republic of the Congo has become the second-largest Ebolavirus outbreak ever recorded, with more than 6,000 confirmed cases and a mortality rate of 48 percent. Despite the scale of the emergency, no licensed vaccine exists against BDBV itself. The only approved ebolavirus vaccine, the live recombinant VSV-EBOV product marketed as Ervebo, was developed and licensed against Ebola virus (EBOV), a distinct but related member of the same viral family. Whether this vaccine could offer any meaningful defense against the virus now circulating in the Congo has been an open and pressing question. A new study from the German Center for Infection Research (DZIF), published in The Lancet Infectious Diseases, provides the first direct evidence in humans that a single dose of the licensed EBOV vaccine can raise immune cells capable of recognizing BDBV, offering a potential immunological bridge in the absence of a dedicated vaccine.

The research focused on T cells, the arm of the adaptive immune system that contributes to viral control and protection against severe disease across a wide range of viral infections. Unlike antibodies, which typically bind to the exposed surfaces of viral proteins with high specificity, T cells recognize short peptide fragments, or epitopes, presented on the surface of infected cells. Because some of these epitopes are conserved across related viral species, T cells raised against one virus can sometimes cross-react with another. This principle underlies hopes that vaccines designed for one pathogen might confer partial protection against its close relatives. Preclinical work had already suggested such a possibility for VSV-EBOV: studies in non-human primates showed partial cross-protection against BDBV, and vaccinated individuals were found to produce antibodies that react with BDBV. What remained unknown was whether the vaccine also induces BDBV-reactive T cells in humans, and if so, how extensive those responses are.

To answer that question, a DZIF team led by Dr. Leonie Mayer and Professor Marylyn Addo of the Institute for Infection Research and Vaccine Development at the University Medical Center Hamburg-Eppendorf, together with Professor Christof Geldmacher and Dr. Rolanda Londt of the Institute of Infectious Diseases and Tropical Medicine at the LMU University Hospital Munich, mapped T-cell responses against three ebolavirus species: Ebola virus, Bundibugyo virus, and Sudan virus (SUDV). The choice of comparison was grounded in viral evolution. The glycoproteins, the surface proteins targeted by both antibodies and T cells, are phylogenetically distant among these species. EBOV and BDBV share 66.3 percent amino acid identity in their glycoproteins, whereas EBOV and SUDV share only 56.3 percent. This gradient of relatedness allowed the researchers to test whether the degree of sequence similarity predicts the strength of cross-reactive immunity.

The team began with a bioinformatic strategy designed to locate the molecular common ground between the viruses. Using multiple sequence alignments, the parallel comparison of amino acid sequences across species, they identified several regions of the glycoproteins that are highly conserved among EBOV, BDBV, and SUDV. These conserved stretches were then tested for their ability to interact with the immune systems of vaccine recipients. The logic is straightforward: if T cells stimulated by the EBOV glycoprotein in the vaccine encounter identical or near-identical peptide sequences presented during a BDBV infection, those cells should be capable of responding to the second virus. The conserved regions therefore represented the most plausible targets of any cross-reactive T-cell response.

The clinical component of the study examined cross-reactive T-cell responses in 20 vaccine recipients, assessed 28 days after a single immunization with VSV-EBOV. The results showed a clear hierarchy of reactivity that tracked with genetic relatedness. Sixteen of the 20 recipients mounted T-cell responses specific to the EBOV glycoprotein, the antigen contained in the vaccine itself. Thirteen of the recipients, however, also showed T-cell responses reactive against the BDBV glycoprotein, and seven showed responses reactive against the SUDV glycoprotein. Notably, most vaccinees who had a positive EBOV-glycoprotein response also carried BDBV-reactive T cells, indicating that cross-reactivity was not a rare curiosity but a common feature of the post-vaccination immune landscape.

The pattern across the three viruses is consistent with the underlying sequence conservation. BDBV, sharing two-thirds of its glycoprotein amino acids with EBOV, elicited cross-reactive T cells in the majority of respondents, while SUDV, with just over half of its glycoprotein sequence in common with EBOV, triggered weaker and less frequent cross-recognition. This correspondence between phylogenetic distance and immunological cross-reactivity strengthens the biological plausibility of the findings and suggests that conserved epitopes within the glycoprotein are indeed the drivers of the shared T-cell response. It also implies that the closer two ebolavirus species are on the evolutionary tree, the more likely a vaccine against one is to prime T cells relevant to the other.

The study demonstrates that a single immunization with the available, licensed EBOV vaccine can induce T-cell cross-reactivity against BDBV and, to a lesser extent, against SUDV. The authors are careful, however, to distinguish between cross-recognition and cross-protection. It is not yet known whether these cross-reactive T cells can contribute to improved clinical outcomes upon actual infection with BDBV. Nevertheless, preclinical studies in non-human primates suggest that T-cell responses are required for vaccine-mediated protection against ebolaviruses, which lends weight to the possibility that the observed cross-reactivity could translate into at least partial clinical benefit. T cells are generally understood to limit viral replication and reduce disease severity even when they do not fully prevent infection, a property that makes them an attractive target in outbreak settings where rapid, broad coverage is needed.

The implications for the current outbreak response are significant. With no BDBV-specific vaccine licensed, public health authorities have few immunological tools to deploy against an epidemic with a mortality rate approaching one in two. The findings provide the first evidence that VSV-EBOV vaccination against ebolavirus induces BDBV-cross-reactive T-cell responses in humans, according to Geldmacher. While the study has limitations due to its small sample size, he concludes that, in the absence of a BDBV-specific vaccine, the results support the systematic evaluation of the EBOV vaccine within clinical trials during the current BDBV outbreak. Such trials would be needed to establish whether the cross-reactive T-cell response observed at the cellular level corresponds to measurable protection against infection, disease, or death.

Several caveats frame the interpretation of the work. The cohort of 20 vaccine recipients is small, and the measurements were taken at a single time point, 28 days after vaccination, leaving open questions about the durability of the cross-reactive response and its behavior after booster dosing. The study also measured T-cell reactivity in vitro rather than protection in vivo, so the functional capacity of these cells to control BDBV infection in a real exposure remains to be demonstrated. Nonetheless, the mapping of conserved glycoprotein epitopes and the demonstration that they are commonly recognized after vaccination provide a concrete mechanistic foundation for future studies. The work also illustrates a broader principle in vaccinology: vaccines designed against one pathogen can seed partially protective immunity against related ones, a concept increasingly relevant to pandemic preparedness.

The research was supported by the DZIF, the European Vaccines Hub for Pandemic Readiness (EVH), and the DFG-funded Collaborative Research Center 1648, Emerging Viruses: Pathogenesis, Structure, Immunity. As the Bundibugyo outbreak continues to grow, the study offers a scientifically grounded rationale for testing an already licensed, mass-producible vaccine against a virus for which no immunization exists. Whether the cross-reactive T cells documented in this work will bend the curve of the epidemic remains to be seen, but the findings mark an important step from laboratory observation toward a potential intervention, and they underscore how understanding the fine details of viral sequence conservation can open unexpected paths in outbreak response.

Subject of Research: Cross-reactive T-cell immunity induced in humans by the licensed Ebola virus vaccine against Bundibugyo ebolavirus

Article Title: Ebola vaccine induces T cell cross-reactivity against Bundibugyo virus in humans

Article References: Ebola vaccine induces T cell cross-reactivity against Bundibugyo virus in humans. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Ebola vaccine, Ervebo, Bundibugyo ebolavirus, T cell cross-reactivity, VSV-EBOV, Sudan virus, glycoprotein, German Center for Infection Research, The Lancet Infectious Diseases, outbreak response, vaccine cross-protection, Democratic Republic of the Congo